Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History LYRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics LYRA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Lyra Therapeutics Inc

LYRA
Current price
8.55 USD -0.01 USD (-0.12%)
Last closed 8.53 USD
ISIN US55234L1052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 13 634 010 USD
Yield for 12 month -40.81 %
1Y
3Y
5Y
10Y
15Y
LYRA
21.11.2021 - 28.11.2021

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

23.00 USD

P/E Ratio

Dividend Yield

Financials LYRA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures LYRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 534 000 USD

Last Year

+1 558 000 USD

Current Quarter

+183 000 USD

Last Quarter

+209 000 USD

Current Year

+1 063 000 USD

Last Year

+1 558 000 USD

Current Quarter

+183 000 USD

Last Quarter

+209 000 USD
EBITDA -44 702 000 USD
Operating Margin TTM -4 347.54 %
Price to Earnings
Return On Assets TTM -28.54 %
PEG Ratio
Return On Equity TTM -195.46 %
Wall Street Target Price 23.00 USD
Revenue TTM 1 185 000 USD
Book Value 2.94 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -65.60 %
Dividend Yield
Gross Profit TTM -29 219 000 USD
Earnings per share -60.50 USD
Diluted Eps TTM -60.50 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation LYRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 12.87
Price Sales TTM 11.51
Enterprise Value EBITDA 0.66
Price Book MRQ 3.52

Technical Indicators LYRA

For 52 Weeks

3.81 USD 34.00 USD
50 Day MA 9.76 USD
Shares Short Prior Month 113 755
200 Day MA 9.63 USD
Short Ratio 0.070
Shares Short 123 908
Short Percent 10.74 %